Kornimate/medical-research-clean huggingface dataset:
dna, blood and skin cell repository for research on als and related neurodegenerative disorders at mayo clinic florida

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Summary: this study is intended to obtain clinical information and establish a repository of dna, rna, peripheral blood monocyte, lymphocyte and skin tissue samples from people with als and related neurodegenerative motor neuron diseases, people with a family history of these conditions, and healthy people with no family history of these disorders. the samples will be used in future research to learn about how these disorders affect people, what causes these conditions, and how the investigators can tell when someone has this kind of disease. future research may also include the generation of stem cells from stored blood cell and skin cell samples. participants will not be paid for taking part in this study.


Eligibility criteria:
inclusion criteria: * als patient 1. clinical diagnosis of possible, laboratory-supported probable, probable or definite als according to modified el escorial criteria, suspected als according to original el escorial criteria, or diagnosis of a neurodegenerative disorder with evidence of als plus extramotor features 2. \> or = 18 years of age and willing to provide consent, or assent, if unable to consent * subject with family history of als or other relevant neurodegenerative disease 1. no personal history of als, als-ftd or other motor neuron disease 2. family history of als, als-ftd in a first, second or third degree blood relative 3. \> or = 18 years of age and willing to provide consent * control 1. no personal or family history (first or second degree blood relative) of als, dementia, parkinson disease or other relevant neurodegenerative disorder 2. \> or = 18 years of age and willing to provide consent exclusion criteria: * als subject and subject with family history of als/als-ftd or other neurodegenerative motor neuron disorder but no personal history of such conditions 1. history of medical disorder that leaves in question whether neurological signs and symptoms potentially related to a neurodegenerative disease may be contributed to by an acquired condition 2. limited mental capacity rendering the subject unable to comply with skin punch biopsy or standard phlebotomy procedures 3. for collection of skin punch biopsy, an increased risk of bleeding complications or allergy to local anesthetic administered at the time of skin biopsy * healthy control subject 1. personal or family history of dementia or other neurodegenerative disease (parkinson disease, alzheimer disease, etc.) 2. limited mental capacity rendering the subject unable to provide written informed consent or comply with standard phlebotomy procedures 3. for collection of skin punch biopsy, an increased risk of bleeding complications or allergy to local anesthetic administered at the time of skin biopsy
central versus peripheral air injection for dalk (deep anterior lamellar keratoplasty)

Conditions: Keratoconus

Summary: different techniques of deep anterior lamellar keratoplasty (dalk) have been introduced to create a uniform recipient bed, thereby reducing complications, such as interface irregularity and opacification encountered with conventional lamellar keratoplasty. the big-bubble technique provides a planned, safe, quick and consistent baring of descemet membrane (dm) by injection of air deep into the stroma. nevertheless, this technique has a long learning curve with a low success rate of big-bubble formation and a high rate of dm perforation when performed by surgeons in training. different modifications to the original technique using intraoperative instruments such as corneal pachymetry, anterior segment optical coherence tomography (oct), and femtosecond laser, have been used to increase the chances of achieving a successful dm detachment from the deep stroma by air injection. even with these innovations, the rate of successful big-bubble formation did not reach 100%. recently, the investigators described a modification to the original big-bubble dalk in which a 27-gauge needle was inserted into the stroma peripherally from the trephination site towards the limbus. the investigators found that air injection peripheral to the trephination can effectively and reproducibly separate the corneal stroma from the descemet membrane (dm). this study was aimed to compare the success rate and complications of big-bubble dalk using central versus peripheral air injection performed by senior cornea fellows under the supervision of an experienced faculty member in an academic hospital.


Eligibility criteria:
inclusion criteria: * patients with moderate (48 d \< mean keratometry \< 55 d) to advanced (mean keratometry ≥ 55 d or immeasurable keratometry) keratoconus were enrolled. exclusion criteria: * history of ocular surgery, concomitant ocular pathologies, such as vernal keratoconjunctivitis, cataract, glaucoma, and retinal abnormalities.

Keywords: deep anterior lamellar keratoplasty big-bubble technique peripheral air injection keratoconus
move to improve physical activity in parkinson's disease

Conditions: Parkinson Disease; Apathy

Summary: apathy is a multi-dimensional behavior characterized by impairments to motivation, planning and initiation; collectively called, goal-directed behavior. it is highly prevalent in patients suffering from neurological disorders such as alzheimer's disease and parkinson's disease (pd) as well as psychiatric disorders such as depression and schizophrenia. in pd, specifically, apathy is one of the more troublesome symptoms. apathetic pd patients have greater disability, lower adherence to treatment plans and caregivers report greater stress and burden. interventions grounded in behavioral economic theories, namely, financial and social incentives often promote positive behavioral change such as weight loss and smoking cessation. however, the effectiveness of these interventions varies across and within conditions and incentive type. it also tends to dissipate when incentives are no longer provided. to date, these approaches have not been used to promote behavior change in pd or other neurological conditions where apathetic behaviors are a pressing problem. the overall goal of this study is to test if behavioral economic approaches will reduce apathy, and subsequently, improve goal-directed behavior in parkinson's disease.


Eligibility criteria:
inclusion criteria: * eligible participants will have a diagnosis of parkinson's disease, and may have either normal cognition or mild cognitive impairment (mci). most eligible participants will have to have smartphones with wifi, application, bluetooth, and text messaging capabilities. the study team does have five smart phone that can be provided to participants who do not have smartphones so as to not exclude these individuals. * eligible participants will have to be mobile as the primary outcome measure for the study is step goals measured on the fitbit. participants will be eligible if they can ambulate successfully with a cane. * participants will also need a study partner to be eligible to participant. this partner can be anyone of the eligible participant's choosing, who also consents to participation in the study. exclusion criteria: * individuals will be excluded if they screen positive for dementia at the screening visit or do not have the decisional capacity to give consent. dementia will be defined as a montreal cognitive assessment (moca) score of \<22. decisional capacity will be tested based on their understanding of study risks and benefits. * individuals will also be excluded if they require a wheelchair or walker, or are unable to ambulate safely. * individuals will be excluded if they are currently participating in another physical activity study, have been told by a physician not to exercise, or are currently pregnant.

Keywords: physical activity social incentives behavioral economics goal-directed behavior motivation
18f-fluorodeoxyglucose positron emission tomography in oncology and neurology

Conditions: Tumors

Summary: this clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test \[positron emission tomography (pet)scan\] in adults who have or are suspected of having cancer and in another group of adults to assess for neurologic conditions.


Eligibility criteria:
inclusion criteria: * known or suspected primary or metastatic tumours * a neurological presentation consistent with the list of indications * 18 years of age or older of either sex * able to provide written informed consent * able to tolerate the physical and logistical requirements of completing a positron emission tomography (pet)scan * karnofsky score \> 60 * women who are nursing may be included in the study if they are able to discontinue breast feeding for 12 hours exclusion criteria: * age \<18 years * pregnant women; if there is a possibility of pregnancy, bloodwork will be drawn to definitively establish pregnancy status * women who are unwilling or unable to discontinue breast feeding for 12 hours post 18f-fluorodeoxyglucose(fdg) administration * subjects who are medically unstable * subjects unwilling to provide informed consent. * subjects who exceed the safe weight limit of the positron emission tomography (pet) imaging bed or who cannot fit through the pet scanner bore

Keywords: positron emission tomography fluorodeoxyglucose fdg (18f-fluorodeoxyglucose) oncology neurology
manipulating narrative presentations of information to encourage good foot care practice in people with and without diabetes mellitus

Conditions: Diabetic Foot; Health Behavior; Foot Diseases

Summary: the study explores the role of health messages (narrative, non-narrative vs. control condition \[no message\]) to enhance good foot care practices among people with diabetes and the general population.


Eligibility criteria:
inclusion criteria: * at least 18 years of age at the time of consent; * able to read and speak the english language; * able and willing to give written informed consent prior to study entry; * able to complete the protocol requirements exclusion criteria: * has a cognitive impairment or acute psychopathology (self-reported formal diagnoses of down syndrome, traumatic brain injury, brain tumour, autism, dementia, schizophrenia, and/or schizoaffective disorder), ie that which could interfere with his or her ability to provide written consent and complete the study * has taken part in any other research on foot care with the university of chichester in the past year

Keywords: foot care narrative diabetes health behaviour health psychology
effects of losartan on myocardial structure in diabetic hypertensive patients with left ventricular

Conditions: Essential Hypertension; Diabetes Mellitus

Summary: the anthypertensive treatment with losartan may have benefits beyond blood pressure reduction on myocardial structure and function in hypertensive diabetic patients. we will evaluate the effect of losartan treatment on structural characteristics of myocardium in hypertensive diabetic patients: 1. left ventricular mass, intraventricular septal thickness, fractional shortening. 2. myocardial qualitative alteration and heterogeneity of myocardial tissue that describes myocardial texture and echodensity, related to collagen deposition; myocardial qualitative alteration will be evaluate by ultrasonic myocardial integrated backscatter signals (ibs) both as peak end diastolic signal intensity and as cardiac cyclic variation 3. alteration of diastolic function as studied by doppler flow velocities across the mitral valve (pulse wave doppler) and pulse wave tissue doppler imaging parameters 4. aortic strain and distensibility (that is in relation with lvh) 5. epicardial adipose tissue measurement (this parameter is related to the visceral fat and may be an easy method to indicate patients with high cardiovascular risk).


Eligibility criteria:
inclusion criteria: * gender: 50% male and 50 % female * age: 40-80 years * race: caucasian * well controlled type ii diabetes : fasting glicemia \ 200 mg/dl; hba1c \< 7% * mild to moderate hypertension (bp\>130/80mmhg; \<160/100mmhg) * left ventricular hypertrophy (lvmi \> 131/110 g/m2 in males/females respectively) exclusion criteria: * other anthypertensive treatment after wash out period of 2 weeks * abnormal heart rest function (ef \< 55%). * valvular heart disease * congenital heart disease * heart failure or prior myocardial infarction * renal disease * liver disease * connective tissue disease * pregnancy or lactation * sensitivity to the study drugs * contraindication from an approved label

Keywords: hypertension diabetes mellitus heart
acute effects of acu-transcutaneous electrical nerve stimulation (acu-tens) on forced expiratory flow volume in one second (fev1) and blood β-endorphin level in subjects with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the objective of this study is to investigate the effectiveness of acu-tens (transcutaneous electrical nerve stimulation applied on acupoints) on lung functions, dyspnoeic symptoms and its association with beta endorphin level in subjects with copd.


Eligibility criteria:
inclusion criteria: * clinical diagnosis with copd exclusion criteria: * allergic to gel * unable to perform spirometry * unable to communicate

Keywords: copd fev1 beta endorphin tens acupuncture
effect of superficial cervical plexus block on post operative nausea and vomiting in tympanomastoid operations

Conditions: Postoperative Nausea and Vomiting

Summary: post operative nausea and vomiting are very common after tympanomastoid operations, in this study we are investigating the effect of superficial cervical plexus block on the incidence and severity of those post operative complications.

various treatments and regimens have been tried to overcome the problem of postoperative nausea and vomiting after tympanomastoid surgery. superficial cervical plexus block seems so promising in this regards as it may reduce the incidence and severity of ponv through 3 mechanisms: primarily through blocking vagal afferents to the middle ear which mediate the vomiting reflex, and secondarily through decreasing pain which aggravates ponv, and finally through decreasing intra and post operative opioid consumption due to adequate analgesia which in turn avoids opioids side effects including ponv. the study group will receive superficial cervical plexus block while the control will receive the same block while given placebo instead of (lidocain/bupivacaine mixture) incidence and severity of ponv will be recoded according to a scale to find the difference between both groups.

Eligibility criteria:
inclusion criteria: * patients belonging to american society of anesthesiologists physical status i-ii. * operation time less than 4 hours. exclusion criteria: * • american society of anesthesiology (asa) physical status ≥ iii. * uncooperative or mentally retarded patients. * known allergy or hypersensitivity to lidocaine or bupivacaine. * patients known to have gastritis or gastro-oesophageal reflux disease (gerd). * history of ponv or motion sickness. * operation duration (short less than 30 minutes or prolonged more than 240 min). * patients with chronic renal disease (serum creatinine level ≥2.0mg/dl) or on renal replacement therapy (dialysis). * patients with chronic cholecystitis (history of recurrent or persistent vomiting) * skin inflammation and cellulitis.

Keywords: nause, vomiting, tympanomastoid operations
safety and effectiveness of giving indinavir, ritonavir, stavudine, and lamivudine to hiv-infected patients who have never received anti-hiv drugs

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe to give indinavir (idv) and ritonavir (rtv) in combination with stavudine (d4t) and lamivudine (3tc) to hiv-positive patients who have never received anti-hiv therapy. this study will look at the effectiveness of this drug combination and side effects.

patients entering this study initiate antiretroviral therapy. for 24 weeks patients receive daily dosages of idv, rtv, 3tc, and d4t. patients are seen at day 1 and at weeks 2, 4, 8, 12, 16, 20, and 24 for physical examinations, pregnancy testing, and blood sampling to monitor cd4 count and viral load. on day 14, blood is drawn frequently for 24 hours for idv and rtv pharmacokinetic sampling. the incidence of serious and drug-related adverse events and of adverse events leading to study discontinuation is tabulated.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv-positive. * are at least 18 years old. * have a viral load of 5,000 copies/ml or greater. * have a cd4 count of at least 50 cells/mm3. exclusion criteria patients will not be eligible for this study if they: * have taken any antiretroviral (anti-hiv) agent. * are pregnant.

Keywords: drug therapy, combination stavudine hiv protease inhibitors cd4 lymphocyte count ritonavir lamivudine indinavir reverse transcriptase inhibitors anti-hiv agents viral load
gastrocnemius stretching on plantar heel pain, foot mobility and function in patients with plantar fasciitis

Conditions: Plantar Fascitis

Summary: the study aims to investigate the effectiveness of gastrocnemius stretching exercises on plantar heel pain intensity, foot mobility, and function in patients with plantar fasciitis.

this randomized controlled trial will include patients diagnosed with plantar fasciitis. participants will be randomly assigned to either a study group performing gastrocnemius stretches or a control group. both groups will receive ultrasound therapy and fascia strengthening exercises. the study group will additionally perform specific gastrocnemius stretching exercises. outcome measures will be assessed before and after 4 weeks of intervention and will include pain intensity, foot mobility using an inversion/eversion device, and function using the foot and ankle ability measure. the study hypothesizes that the study group will demonstrate greater improvements in pain, foot mobility, and function compared to the control group. the study findings could guide physical therapy interventions for patients with plantar fasciitis.

Eligibility criteria:
inclusion criteria: 1. pain reproduced with palpation of the plantar fascia 2. localized and sharp but not radiating 3. worse in the initial step after and an extended period of rest 4. decreased initially after the first steps but exacerbated with increased activityat least 6 weeks 5. unresponsive conservative form of plantar fasciitis care (ie, rest, stretching, full-length silicone insole, prescription nsaids when taken for a period of 2 weeks) exclusion criteria: 1. history of previous steroid injections 2. previous surgery of the foot, lumbar spine disc herniation or back injury 3. patients with rheumatic diseases (e.g., rheumatoid arthritis, spondyloarthropathy, gout disease, enthesopathy, sjogren's syndrome, and systemic lupus erythematosus)
car-pnk cell immunotherapy in muc1 positive relapsed or refractory solid tumor

Conditions: Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Pancreatic Carcinoma; Triple-Negative Invasive Breast Carcinoma; Malignant Glioma of Brain; Colorectal Carcinoma; Gastric Carcinoma

Summary: the purpose of this study is to evaluate the safety and effectiveness of car-pnk cell immunotherapy in patients with muc1 positive relapsed or refractory solid tumor.


Eligibility criteria:
inclusion criteria: male and female subjects with muc1+ malignancies in patients with no available curative treatment options who have limited prognosis (several months to \< 2 year survival) with currently available therapies will be enrolled: 1. eligible diseases: muc1+ malignant glioma of brain, colorectal carcinoma, gastric carcinoma, hepatocellular carcinoma, non-small cell lung cancer, pancreatic carcinoma and triple-negative basal-like breast carcinoma. 2. patients 18 years of age or older, and must have a life expectancy \> 12 weeks. 3. muc1 is expressed in malignancy tissues by immuno-histochemical (ihc). 4. eastern cooperative oncology group (ecog) performance status of 0-2 or karnofsky performance status (kps) score is higher than 60. 5. presence of measurable disease by recist. 6. females of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of car-pnk cells. 7. adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: white blood cell count (wbc) ≥ 2500c/ml, platelets ≥ 50×10\^9/l, hb ≥ 9.0g/dl, lymphocyte (ly) ≥ 0.7×10\^9/l, ly% ≥ 15%, alb ≥ 2.8g/dl, serum lipase and amylase \< 1.5×upper limit of normal, serum creatinine ≤ 2.5mg/dl, aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dl. these tests must be conducted within 7 days prior to registration. 8. ability to give informed consent. exclusion criteria: 1. patients with symptomatic central nervous system (cns) involvement. 2. pregnant or nursing women may not participate. 3. active hiv, hepatitis b virus (hbv) or hepatitis c virus (hcv) infection. 4. serious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or psychiatric or emotional disorders. 5. concurrent use of systemic steroids. recent or current use of inhaled steroids is not exclusionary. 6. the existence of unstable or active ulcers or gastrointestinal bleeding. 7. patients with a history of organ transplantation or are waiting for organ transplantation. 8. patients need anticoagulant therapy (such as warfarin or heparin). 9. patients need long-term antiplatelet therapy (aspirin at a dose \> 300mg/d; clopidogrel at a dose \> 75mg/d).